// startup autopsy
Elixir Pharmaceuticals
Searching for the fountain of youth until the well ran dry
timingSlow Death
Years-long decline before final shutdown · Fatal mistake: Elixir Pharmaceuticals pursued a scientifically compelling but commercially premature anti-aging thesis that could not generate FDA-trackable endpoints within a fundable timeline.
Key Events Timeline
FOUNDING
Elixir Pharmaceuticals founded in the USA to pursue anti-aging and longevity drug research based on emerging caloric restriction science.
FUNDING
Series B funding secured as investor excitement around anti-aging biology peaks; company expands research team.
PRODUCT LAUNCH
Elixir advances a lead compound into early-stage clinical evaluation, generating brief industry attention.
DOWN ROUND
Post-financial crisis funding environment forces a severely down round; key scientific staff begin departing.
SHUTDOWN
Elixir Pharmaceuticals formally closes after exhausting $58M with no approved product and no acquirer found.
MEDIA_MENTION
Elixir Pharmaceuticals is permanently closed. If you feel this is an error, let us know.